Results
1 -
10 of
36Ciceri et al..
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology, Nature Chemical Biology, 2014 A Critical Review of the Role and Limitations of JAK Inhibitors in Myelofibrosis Therapy, Myeloproliferative Neoplasms The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases, International Journal of Hematology Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms, International Journal of Hematology Pathogenetic and clinical impact of JAK2 mutations in chronic myeloproliferative diseases, memo - Magazine of European Medical Oncology